Tornyos K, Silberman H, Solomon A
Cancer Treat Rep. 1977 Aug;61(5):785-7.
Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-week intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day x 7 with each course. The response rate was 46% (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.
本文报告了13例多发性骨髓瘤（MM）患者，这些患者对标准治疗药物无反应或病情复发，且接受了四个或更多疗程的甲环亚硝脲 + 泼尼松治疗（充分的药物试验）。甲环亚硝脲在早餐前口服，每6周给药一次，起始剂量为50mg/m²，随后每个疗程的剂量递增至100、150和200mg/m²。每个疗程泼尼松的剂量为75mg/天，连用7天。缓解率为46%（13例患者中有6例）。没有患者的反应优于一般。在每种情况下均观察到药物毒性严重到足以阻止进一步增加剂量。既往接受卡莫司汀治疗或对先前的烷化剂无反应并不能阻止对甲环亚硝脲 + 泼尼松产生反应。甲环亚硝脲 + 泼尼松在MM中的缓解率与其他药物在类似患者组中所取得的结果相当。
